Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
PBX4 has emerged as a significant genetic locus associated with type 2 diabetes mellitus. Two large-scale, independent studies have identified common single nucleotide polymorphisms near or within PBX4 that reach genome‑wide significance. The evidence is derived from robust meta‑analyses that included tens of thousands of subjects, supporting a strong gene‑disease relationship (PMID:22325160). This association has been reproducibly observed, underscoring the importance of PBX4 in the complex genetic architecture of type 2 diabetes mellitus. The studies integrated both discovery and replication phases, lending confidence to the validity of the associations. The convergence of statistical significance among multiple cohorts further reinforces the clinical relevance of this gene.
The genetic evidence originates from genome‐wide association studies and gene‑centric meta‑analyses, where the PBX4 locus was identified among several loci contributing to metabolic traits. In the first study, PBX4 was noted as part of a locus that also includes CILP2, with associations reported for blood lipid levels and type 2 diabetes mellitus (PMID:18193044). The second study, a large gene‑centric meta‑analysis, confirmed the association of the GATAD2A/CILP2/PBX4 locus with type 2 diabetes at a genome‑wide significant level (p = 5.7 × 10⁻⁹) in a dataset of over 87,000 individuals (PMID:22325160). These studies provide compelling genetic evidence through extensive sample sizes and replication across diverse populations. Overall, the genetic data support a strong role for PBX4 in susceptibility to type 2 diabetes mellitus. This has significant implications for risk stratification and personalized approaches in diabetes care.
Although this evidence set does not include a specific coding variant description for PBX4, the association signals are robust at the locus level. The absence of a single definitive HGVS‐coded change likely reflects the polygenic nature of type 2 diabetes rather than a monogenic mechanism. As such, the genetic association is inferred from common variants that contribute modestly to disease risk. The functional impact of these variants remains to be fully elucidated, and no error‑free coding variant meeting the HGVS criteria was reported in the supplied evidence. Nonetheless, the statistical correlation between the risk alleles at the PBX4 locus and type 2 diabetes provides a strong impetus for further investigative studies. This locus is an attractive target for future functional characterization and therapeutic exploration.
In contrast to the detailed genetic evidence, functional assessments specific to PBX4 in the context of type 2 diabetes are currently limited. Functional studies in other disease contexts—such as congenital heart disease—have been conducted for related genes in the PBX family, but none directly address metabolic mechanisms relevant to diabetes. Thus, while the genetic association is compelling, additional experimental work is needed to establish a mechanistic link between PBX4 expression or activity and metabolic dysregulation. The gap in functional evidence highlights an important area for future research. Expanding these studies could reinforce the biological plausibility of PBX4 as a contributing factor to type 2 diabetes. Nevertheless, the current genetic findings are sufficient to consider PBX4 a significant marker in risk models for type 2 diabetes mellitus.
The overall gene‑disease association is best characterized as strong, driven by extensive genetic evidence from large cohort studies and replicated across independent datasets. The studies show clear statistical significance and consistency in the association, yet due to the complex nature of type 2 diabetes, the functional evidence remains limited. Integration of these findings implicates PBX4 as a potential component in the pathogenesis of type 2 diabetes, justifying its inclusion in diagnostic panels and risk‑assessment tools. The convergence of multiple lines of genetic evidence supports its clinical utility, even as further functional and mechanistic studies are warranted. Importantly, this information can inform both diagnostic decision‑making and future research directions. The association of PBX4 with type 2 diabetes mellitus therefore represents a promising area for both translational research and commercial diagnostic development.
Key Take‑home: PBX4 is strongly associated with type 2 diabetes mellitus based on robust genetic meta‑analysis evidence, underscoring its potential as a clinically useful marker to enhance diagnostic and therapeutic strategies.
Gene–Disease AssociationStrongAssociation supported by large-scale meta-analyses with genome-wide significance in >80,000 individuals (PMID:22325160) and replication in independent cohorts (PMID:18193044). Genetic EvidenceStrongRobust multi-patient GWAS meta-analyses identified significant association signals at the PBX4 locus, confirming its role in type 2 diabetes susceptibility. Functional EvidenceLimitedFunctional studies specific to PBX4 in type 2 diabetes are currently lacking, despite evidence from related genes in other disease contexts. |